Sermorelin: What Researchers Need to Know About the GHRH(1-29) Analog

Sermorelin is the oldest synthetic analog of growth hormone releasing hormone (GHRH) in continuous research use. Long before Tesamorelin, CJC-1295 or modern ghrelin mimetics existed, Sermorelin (GHRH(1-29)) was the reference tool for probing the somatotropic axis. It carried an FDA approval in the early 1990s, fell out of the US market in 2008, and has since returned as a compounded research peptide of enduring academic interest. For researchers, this long history matters: the mechanism is exceptionally well mapped, but the controlled human evidence base in adults remains narrow.

Sermorelingrowth

GHRH(1-29) analog for physiological growth hormone stimulation research

Background: GHRH(1-29) and the History of GEREF

Human growth hormone releasing hormone is a 44-amino-acid hypothalamic peptide. The first 29 residues carry the full biological activity of the native molecule. Sermorelin is simply GHRH(1-29)-NH₂, synthesised as an acetate salt and reproducing the receptor-binding pharmacophore of the native hormone without any stabilising modification.

This makes Sermorelin the structural baseline for the entire GHRH-analog class. CJC-1295 adds a drug-affinity complex for albumin binding; Tesamorelin adds a trans-3-hexenoyl cap to resist dipeptidyl peptidase-4 cleavage. Sermorelin has neither modification. Its plasma half-life is measured in minutes, and it acts through brief, pulsatile stimulation of the GHRH receptor on pituitary somatotropes.

Sermorelin received US Food and Drug Administration approval in 1990 under the brand name GEREF (EMD Serono), initially for use in paediatric growth hormone stimulation tests and later for the treatment of growth hormone deficiency in children. In 2008 the product was withdrawn from the US market. The withdrawal was explicitly stated by the manufacturer as a commercial decision rather than a safety or efficacy issue. Sermorelin then migrated into the compounding-pharmacy and research-peptide space, where it remains available today.

What the Research Shows

Khorram 1997: The Central Adult Human RCT

The pivotal controlled trial of Sermorelin in older adults was conducted by Khorram and colleagues and published in the Journal of Clinical Endocrinology and Metabolism (Khorram O et al., JCEM 1997, PMID 9141536). It remains the most frequently cited Sermorelin reference in the ageing literature for a simple reason: it is the clearest randomised dataset in the adult indication space.

Design: Single-blind, placebo-controlled randomised trial. Nineteen healthy older adults (55-71 years, both sexes). Sermorelin 10 µg/kg administered subcutaneously each night for 16 weeks, compared against placebo.

Key findings: Sermorelin restored the amplitude of nocturnal GH pulses toward younger-adult values. Serum IGF-1 increased significantly versus placebo. Skin thickness (measured by B-mode ultrasound) increased. In the male subgroup, lean body mass (by DXA) increased, and insulin sensitivity (by oral glucose tolerance test) improved. Reported adverse events were mild, most commonly transient injection-site reactions.

The important honest caveat is sample size. Nineteen participants is small by modern RCT standards, and no well-powered replication has followed. The study is quoted precisely because it is effectively the only RCT of its kind for Sermorelin in the adult population.

Mechanism: Feedback-Regulated Pulsatile Release

The mechanistic argument for Sermorelin, articulated across multiple reviews (Walker, Clin Interv Aging 2006, PMC2699646; Prakash & Goa, BioDrugs 1999, PMID 18031173), rests on a distinction from exogenous recombinant GH. Direct rhGH administration produces a sustained, supraphysiological GH elevation, bypassing the hypothalamic-pituitary feedback architecture and requiring no engagement of the pituitary somatotropes.

Sermorelin works upstream. It binds the GHRH receptor on somatotrope cells and stimulates endogenous GH release. Because pituitary somatostatin tone remains intact, the resulting GH output is still subject to negative feedback from IGF-1 and somatostatin. Several consequences follow:

• Pulsatile, not continuous, GH elevation. Endogenous release remains episodic.
• No tachyphylaxis across the dosing windows reported in the early literature.
• IGF-1 elevation within or close to the physiological range, rather than the supraphysiological values typical of exogenous GH.
• A milder adverse-event profile in the published data, with fluid retention, arthralgia and carpal tunnel syndrome markedly less common than in rhGH cohorts.

This mechanistic profile is the reason Sermorelin continued to interest researchers after its market withdrawal. The pharmacology is physiological rather than supraphysiological.

Contemporary Reviews

Two recent reviews situate Sermorelin in the modern GH-axis literature. Fernández-Garza (Frontiers in Aging 2025, PMID 40260058) surveys the somatotropic axis in older adults, the associated body-composition and metabolic changes, and the evidence for GHRH-based intervention. Ishida and colleagues (JCSM Rapid Communications 2020) review the GH-secretagogue class as a whole and place Sermorelin as the historical reference against which newer molecules (Tesamorelin, CJC-1295, MK-0677) are compared.

Beyond Khorram 1997, the published Sermorelin evidence in adults consists mainly of observational series, pharmacology studies and uncontrolled case reports. Randomised replication at modern sample sizes does not exist. Researchers should read claims in this space with that evidence limitation in mind.

Sermorelin in Context: The Two GHRH Analogs We Carry

Within the GHRH-analog class, PeptidesDirect offers two compounds, and they occupy distinct research roles.

Sermorelin is unmodified GHRH(1-29). It has the purest mechanistic profile of the class: short half-life, pulsatile GHRH stimulation, full feedback regulation. Its controlled human evidence base is limited to Khorram 1997 (n=19) and a scatter of smaller studies.

Tesamorelin is a hexenoyl-stabilised GHRH(1-44) analog. It carries the full pivotal Phase III clinical programme (Falutz NEJM 2007, Stanley Lancet HIV 2019, Baker Arch Neurol 2012, Ellis 2025), FDA approval, and over 800 patients in pooled randomised analysis. It is the reference compound for the class.

The two are complementary rather than interchangeable. Sermorelin is the structural baseline with the cleaner pulsatile kinetics; Tesamorelin is the clinically validated, longer-lived analog. Research protocols comparing them directly are rare in the published literature.

Quality Criteria When Sourcing Sermorelin

Sermorelin is a 29-residue linear peptide with a C-terminal amide. The synthesis is chemically well understood, but deletion sequences and aspartimide formation remain the main side-product risks. Correct amidation at the C-terminus is essential for receptor binding.

EU shipping: For European researchers, PeptidesDirect ships from within the EU. No customs, no import fees, delivery in two to three working days with tracking.

Reconstitution

Regulatory Context

Sermorelin (GEREF) received US Food and Drug Administration approval in 1990, with a clinical indication focused on paediatric growth hormone stimulation testing and paediatric growth hormone deficiency. The manufacturer withdrew the product from the US market in 2008. The withdrawal was explicitly commercial, not safety-driven; no black-box warning, no product recall and no FDA enforcement action preceded it. After 2008 Sermorelin migrated into the compounding-pharmacy space in the United States and into the research-peptide supply chain globally.

Sermorelin is listed under WADA S2 (Peptide Hormones, Growth Factors and Related Substances) as a prohibited substance at all times in competitive sport, in common with the wider GHRH-analog class.

In the European Union, Sermorelin is not currently authorised as a medicinal product. It is supplied exclusively as a reference compound for in vitro and preclinical research. It is not a medication, not for human consumption, and not intended for diagnostic or therapeutic use.

Honest Reading of the Evidence Base

Sermorelin occupies an unusual scientific position. The mechanistic case for GHRH(1-29) as a physiological secretagogue is strong and widely cited. The FDA history documents a peptide that cleared regulatory review more than three decades ago. And yet the controlled adult-human evidence base rests largely on a single 19-participant RCT from 1997. Subsequent literature is dominated by observational series, paediatric stimulation-test data (the original GEREF indication) and review articles revisiting the original findings.

This is not a reason to ignore Sermorelin. It is a reason to read it correctly: as the structural and historical reference peptide of the GHRH-analog class, with a clean mechanism, a solid pharmacology record, and a narrow but real controlled clinical dataset in adults. Researchers designing protocols should weigh the evidence at Khorram 1997 (n=19) for what it actually is, rather than what the subsequent popular literature has sometimes extrapolated it to say.

Among the GHRH analogs available today, Sermorelin remains the cleanest mechanistic probe: the original, unmodified GHRH(1-29) pharmacophore, without half-life extensions or receptor-affinity modifications. That status, together with its three-decade clinical history, keeps it relevant to research programmes investigating the somatotropic axis in ageing.